Boy holding a glowing balloon, symbolising a clearer future for children through evidence-based myopia control.
EVIDENCE · MEASUREMENT · INTERVENTION

The international evidence hub for myopia control.

Clinical evidence changes faster than most websites do. Myopia.website organises current research, measurement tools, treatment strategies and safety evidence into one continuously updated resource.

SCOPE
Evidence synthesis for clinicians and researchers
REFERENCE SET
Verified primary studies, reviews and consensus documents
TOOLS
Axial length centiles and educational trajectory modelling
SISTER PROJECT
Polish evidence dossiers at Krótkowzroczność.pl
EVIDENCE UPDATE · SEPTEMBER 2026

A three-year direct comparison joins the RLRL evidence base.

Published 10 September 2026, Ref. 23 compares EyeRising / RLRL (n = 40) with orthokeratology (n = 46) in a retrospective observational cohort of 86 children during three years of active treatment. The study does not establish causal superiority.

Current verified registry: September 2026 · Ref. 1–23 · data status 17 September 2026. Previous verified registry: August 2026 · Ref. 1–22.

3 YEARS

Active-treatment direct comparative cohort

86 CHILDREN

EyeRising / RLRL vs orthokeratology

23 VERIFIED REFERENCES

Current RLRL evidence registry

DEVICE-SPECIFIC EVIDENCE

Findings do not transfer to unrelated emitters

01 LIVE EVIDENCE MAP

Every question in myopia control leads to a node.

Interventions on the left, measurement and timing on the right. Each node opens a synthesis with the primary studies behind it.

CENTRAL NODE
MYOPIA
CONTROL
Slowing axial elongation in childhood, with monitoring and safety as part of the intervention.
MEASUREMENT · TIMING · SAFETY
{{ node.label }} {{ node.tag }}
02 WHAT WORKS NOW

The state of the evidence, not a ranking of products.

No single treatment is best for every patient. What follows is the maturity of the evidence base per strategy, and where it stops.

{{ tier.kicker }} {{ tier.title }}
03 AXIAL LENGTH LAB

Read an axial length against a published centile chart.

Enter age, sex and axial length. The Lab places each eye on the Europe + Australia centile reference, then models refractive trajectory scenarios as an optional second step.

{{ f.label }}
{{ f.tag }}
OPEN THE AXIAL LENGTH LAB →

Educational tool. It is not an automated diagnosis and not an individual treatment recommendation.

CENTILE REFERENCE · MALES AL / mm
{{ previewChart }}
P97 P75 P50 P25

Kneepkens SCM, Lingham G, van Hemert DJ, et al.; CREAM-Kids Consortium. Global Axial Length Centile Charts. JAMA Ophthalmology. doi:10.1001/jamaophthalmol.2026.2539 · Supplement 1, eTable 3 · Europe + Australia.

04 TREATMENT LANDSCAPE

Combination therapy first. RLRL second. Defocus optics third.

Order follows the strategic hierarchy used across this project. Each entry states its evidence basis as the actual source type, not a maturity grade. Absolute effects come from the study that defines the entry; where a dimension has no comparable published data, the cell reads Evidence insufficient / evolving.

1
STRONGEST CURRENT MODEL OF INTENSIVE MYOPIA-PROGRESSION CONTROL

Combination therapy

RLRL + defocus optics / myopia-control spectacle lenses

In the study that defines this row, the two mechanisms together outperformed either one alone. Combining them is the most intensive control strategy in this synthesis: neither optical defocus nor red light on its own reproduced the combined effect.

{{ s.label }}
{{ s.value }}
{{ s.note }}
WHAT THE STUDY REPORTS

Adjusted mean yearly axial change was −0.13 mm with combination therapy, against −0.04 mm for red light alone and +0.16 mm for defocus lenses alone (p < 0.0001). Spherical equivalent moved +0.09 D in the combined group while both monotherapy groups progressed. No adverse event was observed or reported in any of the three groups.

WHAT IT DOES NOT SETTLE

A retrospective cohort with no single-vision control arm and unbalanced group sizes, adjusted through a mixed model. Cycloplegia was not performed at every visit, so the refractive figures can be confounded. The authors call for randomised trials to validate the synergy.

2
HIGHEST-RANKED MONOTHERAPY IN THIS SYNTHESIS

Repeated low-level red-light therapy

RLRL · red light

RLRL is supported by strong short-term randomized efficacy evidence and by multicentre real-world observation extending up to five years. Safety evidence now includes dedicated retinal imaging and longer clinical follow-up, while rare-event risk remains unresolved. Findings must not be transferred to unrelated red-light emitters.

{{ s.label }}
{{ s.value }}
{{ s.note }}
3
ESTABLISHED OPTICAL MONOTHERAPY

Defocus optics

Myopia-control spectacle lenses

One category, not a product ranking. DIMS, HAL and related lenslet designs are technologies within myopia-control spectacle lenses; they are treated here as a single strategy built on peripheral myopic defocus.

{{ s.label }}
{{ s.value }}
{{ s.note }}
FURTHER STRATEGIES · IN PROJECT HIERARCHY ORDER
STRATEGY EVIDENCE BASIS AXIAL-LENGTH EFFECT INVASIVENESS MONITORING
{{ m.rank }} {{ m.name }} {{ m.category }}
{{ b }}
{{ m.axial }}
{{ m.invasiveness }}
{{ m.monitoring }}
{{ m.sign }}
SAFETY CONSIDERATIONS

{{ m.safety }}

COMBINATION EVIDENCE

{{ m.combination }}

MAIN LIMITATION

{{ m.limitation }}

DEFINING STUDY {{ m.source }} {{ m.hrefLabel }} ↗
MODEL PARAMETER · NOT A MEASURED EFFECT

The reduction percentages used by the Axial Length Lab trajectory model (defocus optics ≈ 60%, RLRL 80–95%, atropine 0.01% 10–15%) are explicit scenario parameters, harmonising results reported in dioptres and millimetres. They are auditable model inputs, not per-patient efficacy, and they are not a common scoring scale across products.

05 KNOWLEDGE NODE

Repeated Low-Level Red-Light Therapy

Strong randomized short-term efficacy, real-world clinical observation extending up to five years, initial randomized evidence outside East Asia and a substantially broader retinal-safety literature. The unresolved questions have changed: rare-event long-term safety, broad international generalisability and the optimal way to discontinue treatment remain open.

{{ s }}
OPEN THE RLRL NODE →
06 SAFETY NODE

RLRL and Atropine — Concurrent Use Is Contraindicated

The Eyerising instructions for use list a dilated pupil and medicines such as atropine among the contraindications. For that device, concurrent use is not permitted. Comparative trials did not expose children to both therapies and therefore cannot establish the safety of concurrent use.

{{ p }}
OPEN THE SAFETY NODE →
07 CLINICAL FRAMEWORKS

The Nowak Method

A physician-supervised clinical implementation framework translating current evidence into a structured pathway for measurement, eligibility assessment, intervention selection, monitoring and treatment modification.

Myopia.website indexes it as one referenced framework among clinical resources. The full protocol, its revisions and its versioned record stay with the authoring source.

{{ step.n }}
{{ step.title }} {{ step.body }}
08 EVIDENCE LIBRARY

Every claim on this site resolves to one of these.

The current September 2026 RLRL registry contains Ref. 1–23; the previous verified August 2026 registry was Ref. 1–22. Stable Ref. numbers identify records, while the complete library below is displayed newest first. Additional independent evidence and the wider myopia library remain distinct records. Study design is shown alongside each claim.

42 records shown

10 SEP 2026
REF. 23

Three-year Comparative Efficacy and Safety of Repeated Low-level Red-light Therapy and Orthokeratology for Myopia Control in Children

Aiqin Nie, Jing Xie, Yingshi Zou, Ming-Ming Yang, Yanxian Chen, Mingguang He · Ophthalmology and Therapy. Published 10 September 2026.

EyeRising / EMMD · PEER-REVIEWED ORIGINAL RESEARCH · RETROSPECTIVE OBSERVATIONAL COMPARATIVE STUDY

During 3 years of active treatment, RLRL was associated with substantially less axial elongation than orthokeratology in this cohort.

STUDY / COMPARATOR

Single-centre, nonrandomized cohort of 86 children aged 6–16: EyeRising / RLRL n = 40; orthokeratology n = 46.

36-MONTH AXIAL CHANGE

0.00 ± 0.28 mm vs +0.45 ± 0.20 mm; P < 0.001. Axial shortening ≥ 0.05 mm: 40.00% vs 2.17%. Complete control (< 0.10 mm/year): 82.5% vs 37.0%.

SAFETY

No serious treatment-related adverse events; BCVA remained stable. Transient glare: 1/40; afterimages: 40/40, all resolved within 5 minutes, with no discontinuations. One transient focal OCT finding after 24 months resolved by 36 months without visual-acuity loss or treatment interruption; causality was not established.

CONFLICT OF INTEREST

Aiqin Nie, Jing Xie, Yingshi Zou, Ming-Ming Yang and Yanxian Chen: nothing to disclose. Mingguang He: director and shareholder of Eyerising Ltd and Eyerising International Pty Ltd.

MAIN LIMITATIONS

Retrospective, single-centre, nonrandomized Chinese cohort selected for adherence and complete follow-up. Final measurements were during active treatment; no washout or post-treatment assessment. Persistence after cessation and causal superiority are unknown; generalisability to other populations is uncertain.

PROTOCOL USED IN THIS STUDY

EyeRising device by Suzhou Xuanjia Optoelectronics Technology Co., Ltd.; 650 ± 10 nm; two 3-minute sessions daily, 7 days per week, at least 4 hours apart, during 3 years of active treatment. This describes the study protocol, not a universal or current regional IFU.

2026
REF. 07

Three-year efficacy and safety of repeated low-level red-light therapy for myopia control: a multicentre real-world study

Yanping Chen, Wei Wang, Ruilin Xiong, et al. · British Journal of Ophthalmology. 2026;110(9):1028–1035.

STUDY TYPE

REAL-WORLD OBSERVATIONAL STUDY

KEY FINDING

Clinical, OCT and ERG observations extend to treatment durations of at least three years.

WHAT IT SUPPORTS

Multicentre observations across treatment durations including ≥3 years; clinical, OCT and ERG assessment.

MAIN LIMITATION

Observational duration strata, not a three-year randomized comparator; continuation/selection bias.

2026
REF. 06

Repeated low-level red-light therapy combined with orthokeratology for myopia control in Spain: a randomised controlled study

María José Fernández Fidalgo, Victoria D. Ferigo Ferrel, Yue Wu, et al. · British Journal of Ophthalmology. Final issue: 2026;110(7):771–777.

STUDY TYPE

RCT · COMBINATION

KEY FINDING

Greater axial-length control with RLRL plus orthokeratology than with orthokeratology alone.

WHAT IT SUPPORTS

Randomized Spanish/European evidence for adding RLRL to orthokeratology.

MAIN LIMITATION

Small, single-site, non-blinded combination trial; not European RLRL-monotherapy replication.

2026
REF. 20

Adjunctive repeated low-level red-light therapy enhances structural outcomes in optical myopia control: A meta-analysis

Nian Zhang, Yayan You, Rui Li, Bingjie Shi. · Photodiagnosis and Photodynamic Therapy. 2026;59:105512.

STUDY TYPE

META-ANALYSIS · COMBINATION

KEY FINDING

Eight-study synthesis examines adjunctive RLRL with orthokeratology or DIMS.

WHAT IT SUPPORTS

Eight-study synthesis of adjunctive RLRL with orthokeratology or DIMS versus optical monotherapy.

MAIN LIMITATION

Combination efficacy does not establish compatibility with every device instruction for use.

2026
REF. 09

Efficacy of red light for myopia control from age 2 to 24 with diverse treatment periods: A real-world study

Yanxian Chen, Yue Wu, Lili Wang, Zhuoting Zhu, et al. · Photodiagnosis and Photodynamic Therapy. 2026;59:105481.

STUDY TYPE

PROSPECTIVE REAL-WORLD COHORT

KEY FINDING

Routine-care outcomes in 2,825 participants across 20 hospitals, with treatment periods up to 36 months.

WHAT IT SUPPORTS

2,825 participants, 20 hospitals, ages 2–24 and treatment periods up to 36 months.

MAIN LIMITATION

Broad routine-care cohort; no long-term randomized comparator; does not establish international generalisability.

2026
REF. 16

Safety analysis of repeated low-level red light therapy on cone mosaic and microvasculature by adaptive optics scanning laser ophthalmoscopy

Yu Yue, Ni Zhang, Ke-Yu Liu, Yuan-Yuan Zhong, Han Wang, Shu-Lin Liu, Wen-Juan Wan, Yan-Lai Zhang, Wen-Li Deng. · Photodiagnosis and Photodynamic Therapy. 2026;59:105473.

STUDY TYPE

CROSS-SECTIONAL SAFETY STUDY

KEY FINDING

Adaptive-optics imaging assesses cone mosaic and retinal microvasculature.

WHAT IT SUPPORTS

Adaptive-optics assessment of cone mosaic and retinal microvasculature.

MAIN LIMITATION

Cross-sectional imaging; not a long-term randomized safety study and not proof of zero rare-event risk.

2026
REF. 05

Efficacy of repeated red-light laser therapy for myopia control in Australian children: a pilot randomised controlled trial

Gabriella Bulloch, Ziyi Qi, Yuri Yin-Moe Aung, et al. · Clinical & Experimental Optometry. 2026.

STUDY TYPE

PILOT RCT

KEY FINDING

Initial randomized efficacy evidence from a 34-child Australian multi-ethnic pilot.

WHAT IT SUPPORTS

Initial randomized efficacy evidence in an Australian multi-ethnic population.

MAIN LIMITATION

Only 34 children; does not establish equivalent efficacy across ethnicities.

2026
REF. 19

Repeated low-level red light modulates retinal metabolic alterations in lens-induced myopic chicks

Chengjie He, Yanjing Huang, Shiran Zhang, Jingni Li, Jiangbo Liang, Jingyi Peng, Yue Wu, Ying Hong, Ying-Feng Zheng, Mingguang He. · Journal of Photochemistry and Photobiology B. 2026;278:113432.

STUDY TYPE

ANIMAL / MECHANISTIC STUDY

KEY FINDING

Retinal metabolic changes were studied in lens-induced myopic chicks, not children.

WHAT IT SUPPORTS

Retinal metabolic responses in lens-induced myopic chicks.

MAIN LIMITATION

Animal evidence, not human clinical efficacy or proof of a metabolic mechanism in children.

2026
REF. 12

Duration-Dependent Efficacy and Clinical Safety of Repeated Low-Level Red-Light Therapy for Paediatric Myopia: A Systematic Review and Meta-Analysis

Lee-Yuan Lin, Cheng-Hao Hsu, Hung Su, et al. · Clinical & Experimental Ophthalmology. 2026;54(5):630–652.

STUDY TYPE

SYSTEMATIC REVIEW · META-ANALYSIS

KEY FINDING

Randomized efficacy and clinical-safety findings vary with follow-up duration and outcome certainty.

WHAT IT SUPPORTS

Duration-dependent randomized efficacy and clinical safety synthesis.

MAIN LIMITATION

Follow-up and outcome certainty differ; comprehensive longer-term retinal safety remains needed.

2026
REF. 22

Expert Opinion on Myopia Tapering: Strategies for Managing Myopia Progression

Yanxian Chen, Zhuoting Zhu, Yuri Yin-Moe Aung, Yuzhou Zhang, Yueye Wang, Jason CS Yam, Mingguang He. · Ophthalmic Epidemiology. 2026;33(3):306–309. Epub 18 Feb 2026.

STUDY TYPE

EXPERT OPINION · NOT A TAPERING TRIAL

KEY FINDING

Expert-proposed reduction of treatment frequency with continued monitoring; not a validated tapering trial.

WHAT IT SUPPORTS

Expert-proposed gradual reduction of treatment frequency with continued monitoring.

MAIN LIMITATION

No randomized validation of an optimal RLRL tapering schedule or superiority over abrupt cessation.

2026
REF. 14

Clinical efficacy and cost-effectiveness of four myopia control interventions in children: a single-center retrospective study

Daohuan Kang, Lu Yuan, Carla Lanca, et al. · Scientific Reports. 2026;16:9126.

STUDY TYPE

RETROSPECTIVE COMPARATIVE STUDY

KEY FINDING

One-year mean axial change: 0.06 mm with RLRL versus 0.42 mm with single-vision lenses; observed difference −0.36 mm.

WHAT IT SUPPORTS

Four-strategy, single-centre clinical and cost-effectiveness comparison in 206 children.

MAIN LIMITATION

Nonrandomized allocation; one-year horizon; economics are specific to the study setting.

2026
REF. 13

Exploring the efficacy of repeated low-level red-light therapy in retarding childhood myopia progression: updated systematic review and meta-analysis

Chen Liu, Yating Zhou, Zongyue Zhan, Xiaofeng Li. · Frontiers in Medicine. 2026;13:1713885.

STUDY TYPE

SYSTEMATIC REVIEW · META-ANALYSIS

KEY FINDING

Pooled randomized outcomes cover axial length, refraction and subfoveal choroidal thickness.

WHAT IT SUPPORTS

Updated pooled randomized evidence for axial length, refraction and subfoveal choroidal thickness.

MAIN LIMITATION

Devices, comparators and follow-up vary; pooled efficacy does not validate unrelated red-light emitters.

2026
REF. 21

Axial Length Control Using Repeated Low-Level Red Light Combined with Orthokeratology Compared with Orthokeratology Alone in Rapidly Progressing Myopic Children

Alkut Elham, Xiangjun Meng. · Clinical Ophthalmology. 2026;20:571867.

STUDY TYPE

RETROSPECTIVE COHORT · NOT RCT

KEY FINDING

Retrospective comparison in 72 rapidly progressing children; corrected analyses must be read with the corrigendum.

WHAT IT SUPPORTS

RLRL plus orthokeratology in 72 rapidly progressing children aged 8–14; propensity/IPTW analyses.

MAIN LIMITATION

Retrospective allocation. A June 2026 corrigendum corrects per-protocol analyses; read both records.

2026
REF. 08

Five-year efficacy and safety of repeated low-level red light therapy for myopia control in children: a multicenter, real-world study

Zhang J, Yu J, Zou H, Xu Y. · Advances in Ophthalmology Practice and Research. 2026.

STUDY TYPE

RETROSPECTIVE REAL-WORLD COHORT

KEY FINDING

Published real-world observation extends up to five years across 12 clinical sites.

WHAT IT SUPPORTS

Published multicentre clinical observation extends up to five years across 12 clinical sites.

MAIN LIMITATION

Journal pre-proof; unequal follow-up and nonrandomized design. Not all participants were observed for five years; not a five-year RCT.

2026
REF. 17

An analysis of retinal safety when using a Laser based low-level red light therapy device for myopia

Karl Schulmeister, John Marshall. · medRxiv. 2026.

STUDY TYPE

PREPRINT · NOT PEER REVIEWED · DEVICE-SPECIFIC

KEY FINDING

Radiometric / laboratory safety analysis of EMMD using modelled exposure thresholds; not a long-term clinical safety study.

WHAT IT SUPPORTS

Laboratory/radiometric analysis of the Eyerising Myopia Management Device (EMMD).

MAIN LIMITATION

Version 1 preprint; modelling and selected exposure thresholds for one device, not a clinical long-term safety cohort.

DEVICE
Eyerising Myopia Management Device (EMMD)
STATUS
PREPRINT · NOT PEER REVIEWED · DEVICE-SPECIFIC
2026
ADDITIONAL

Global Axial Length Centile Charts

Kneepkens SCM, Lingham G, van Hemert DJ, et al.; CREAM-Kids Consortium · JAMA Ophthalmology

CENTILE REFERENCE

Age- and sex-specific axial length centiles; Europe + Australia set used by the Lab.

2026
REF. 18

Impact of Myopia Control Interventions on Choroidal Thickness in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Clara Martinez-Perez, Ana Paula Oliveira. · Ophthalmology Science. E-published 17 Dec 2025; issue 2026;6(2):101039.

STUDY TYPE

SYSTEMATIC REVIEW · META-ANALYSIS

KEY FINDING

Human choroidal-thickness synthesis includes 11 randomized trials and 2,190 eyes.

WHAT IT SUPPORTS

Human biomarker evidence: choroidal-thickness changes across 11 RCTs / 2,190 eyes.

MAIN LIMITATION

Treatment-associated biomarker response does not establish a single causal mechanism. Online December 2025; issue 2026.

2025
REF. 11

Efficacy comparison of atropine, orthokeratology and repeated low-level red-light therapy for myopia control in children: a systematic review and network meta-analysis

Zetong Zheng, Xue Jiang, Rongxin Chen, Li Dong. · British Journal of Ophthalmology. 2025;109(11):1215–1220.

STUDY TYPE

SYSTEMATIC REVIEW · NETWORK META-ANALYSIS

KEY FINDING

Comparative synthesis includes 41 randomized trials and 6,434 eyes.

WHAT IT SUPPORTS

Comparative synthesis of RLRL, atropine and orthokeratology: 41 RCTs / 6,434 eyes.

MAIN LIMITATION

Bayesian network comparisons combine direct and indirect evidence; not a single head-to-head trial.

2025
ADDITIONAL

IMI — Interventions for Controlling Myopia Onset and Progression 2025

International Myopia Institute · Investigative Ophthalmology & Visual Science

SYSTEMATIC REVIEW

Reference review of mature and developing interventions; does not replace primary extraction.

2025
REF. 04

The Effect of Repeated Low-Level Red Light Versus 0.01% Atropine Treatment on Axial Length and Choroidal Parameters in Children with Myopia

Xuena Pang, Aicun Fu, Guangying Zheng, Weiqun Wang, Mei Zhong, Lili Shang, Minghang Chang, Xuemin Jin. · Ophthalmology and Therapy. 2025;14(8):1739–1754.

STUDY TYPE

RANDOMIZED COMPARATIVE STUDY

KEY FINDING

Axial-length and choroidal outcomes from the initial six-month period of the crossover trial.

WHAT IT SUPPORTS

Axial-length and choroidal responses during RLRL versus atropine 0.01%.

MAIN LIMITATION

Single-blind and short-term; initial six-month period of the crossover trial reported in Ref. 3. Do not double-count participants.

2025
ADDITIONAL

Cone Density Changes After Repeated Low-Level Red Light Treatment in Children With Myopia

Xinyi Liao, et al. · JAMA Ophthalmology. 2025;143(6):480–488.

STUDY TYPE

RETROSPECTIVE MULTICENTRE COHORT

KEY FINDING

In 99 children, prior RLRL exposure was associated with reduced paracentral cone density and subtle imaging differences.

MAIN LIMITATION

Association does not establish irreversible damage; functional significance and causality remain uncertain.

2025
REF. 10

Efficacy of interventions for myopia control in children: A systematic review with network meta-analyses

Diana Chabané Schmidt, Anders Hvid-Hansen, Nina Jacobsen, et al. · Acta Ophthalmologica. 2025.

STUDY TYPE

SYSTEMATIC REVIEW · NETWORK META-ANALYSIS

KEY FINDING

Network synthesis compares myopia-control interventions using direct and indirect evidence.

WHAT IT SUPPORTS

Broader comparative synthesis of interventions for myopia control.

MAIN LIMITATION

Network comparisons may include indirect evidence; rankings depend on transitivity and heterogeneous protocols.

2025
REF. 03

Effect of Repeated Low-Level Red Light Versus 0.01% Topical Atropine on Myopia Progression: A Randomized Crossover-Controlled Trial

Xuena Pang, Xuemin Jin, Aicun Fu, et al. · Translational Vision Science & Technology. 2025;14(4):22.

STUDY TYPE

RANDOMIZED CROSSOVER TRIAL

KEY FINDING

RLRL was compared with atropine 0.01%; the study did not test concurrent exposure.

WHAT IT SUPPORTS

Direct comparison of RLRL and atropine 0.01%, not their concurrent use.

MAIN LIMITATION

Crossover and washout interpretation; small single-centre cohort. Ref. 4 reports the initial period of the same trial, not an independent population.

2025
ADDITIONAL

Synergistic effect of defocus incorporated multiple segment glasses and repeated low level red light therapy against myopia progression

Yang Y, Liu S, Gao W, Wang L, Liu N, Zhang S, Yang L, Cheng L · Scientific Reports

RETROSPECTIVE COHORT

190 children, 380 eyes. Adjusted yearly axial change −0.13 mm combined, −0.04 mm red light alone, +0.16 mm defocus lenses alone (p < 0.0001). No adverse event reported.

2025
ADDITIONAL

Safety of repeated low-level red-light therapy for myopia control

Ong J, et al. · Asia-Pacific Journal of Ophthalmology

SYSTEMATIC REVIEW

Historical safety review: 20 studies, 2,380 children; median follow-up 9 months, longest 24 in that review. Not the current maximum follow-up horizon.

2025
REF. 15

Safety of and chorioretinal circulation during repeated low-level red-light therapy for myopic children

Zhaoxin Jiang, Shuyu Chen, Renchun Wang, Jin Ma. · Clinical & Experimental Ophthalmology. 2025;53(2):119–132. Epub 5 Nov 2024.

STUDY TYPE

RCT · RETINAL SAFETY

KEY FINDING

Dedicated clinical-safety and chorioretinal-circulation assessment in myopic children.

WHAT IT SUPPORTS

Dedicated assessment of clinical safety and chorioretinal circulation.

MAIN LIMITATION

Safety inference is limited to the studied protocol, observation period and measured endpoints.

2024
ADDITIONAL

Interventions to increase time spent outdoors for preventing incidence and progression of myopia in children

Cochrane Eyes and Vision Group · Cochrane Database of Systematic Reviews

SYSTEMATIC REVIEW

5 RCTs, 10 733 children. Moderate certainty for preventing onset.

2024
ADDITIONAL

Red light instruments for myopia exceed safety limits

Ostrin LA, et al. · Ophthalmic and Physiological Optics

OTHER DEVICE · OUTSIDE EMMD CLINICAL SCOPE

Exposure measured for two devices. Conclusions are device-dependent and do not generalise to the class.

2023
ADDITIONAL

Evaluation of the Prevalence of Refractive Defects and Ocular Function in a Group of 1518 Children Aged 8 Years in Northwestern Poland

Modrzejewska M, Durajczyk M · Journal of Clinical Medicine

REAL-WORLD EVIDENCE

Regional cycloplegic prevalence series; not a national time series.

2023
REF. 02

Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial

Xiangui He, Jingjing Wang, Zhuoting Zhu, et al. · JAMA Network Open. 2023;6(4):e239612.

STUDY TYPE

RCT

KEY FINDING

Reduced myopia incidence in the studied premyopic population.

WHAT IT SUPPORTS

Premyopia prevention in children selected for elevated myopia risk.

MAIN LIMITATION

Selected high-risk Chinese school population; not universal preventive efficacy.

2022
ADDITIONAL

Sustained and rebound effect of repeated low-level red-light therapy on myopia control: A 2-year post-trial follow-up study

Ruilin Xiong, et al. · Clinical & Experimental Ophthalmology. 2022;50(9):1013–1024.

STUDY TYPE

POST-TRIAL FOLLOW-UP

KEY FINDING

Direct cessation evidence: continued treatment sustained benefit; a modest rebound was reported after stopping.

MAIN LIMITATION

Selected post-trial groups and substantial attrition; not a randomized tapering-versus-abrupt-stop comparison.

2022
REF. 01

Effect of Repeated Low-Level Red-Light Therapy for Myopia Control in Children: A Multicenter Randomized Controlled Trial

Yu Jiang, Zhuoting Zhu, Xingping Tan, et al. · Ophthalmology. 2022;129(5):509–519.

STUDY TYPE

RCT

KEY FINDING

Adjusted axial elongation at 12 months: 0.13 vs 0.38 mm; reported adjusted between-group difference 0.26 mm.

WHAT IT SUPPORTS

Foundational 12-month efficacy versus single-vision spectacles.

MAIN LIMITATION

Single-blind; no sham arm; Chinese cohort; device-specific exposure.

2020
ADDITIONAL

Effect of High Add Power, Medium Add Power, or Single-Vision Contact Lenses on Myopia Progression in Children

Walline JJ, et al. · JAMA

RCT

BLINK trial. AL change 0.42 mm vs 0.66 mm over 3 years with +2.50 D add.

2015
ADDITIONAL

School-Based Intervention of Outdoor Activity on Myopia Among Children in China

He M, et al. · JAMA

RCT

Cumulative incidence 30.4% vs 39.5% over 3 years. The AL difference was not statistically significant.

09 EXPERT CONTRIBUTORS

A reviewed platform, not one clinician's page.

Contribution is structured by role. Every node records who wrote it, who reviewed it and against which sources.

{{ r.tag }}
{{ r.title }} {{ r.body }}
NAMED CONTRIBUTOR
Prof. Michał Szymon Nowak Epidemiology · RLRL · The Nowak Method

Attribution is scoped to the nodes where the contribution is substantive. Other nodes carry other authors and reviewers, and the platform is designed to hold ophthalmologists, optometrists, researchers and reviewers on equal footing.

10 SISTER PROJECT

Krótkowzroczność.pl

The Polish evidence and public-information platform on childhood myopia, treatment methods, axial-length monitoring and clinical safety.

Two complementary entities, not one site in two languages. The Polish platform holds the full dossiers, the Polish treatment landscape and public education. Myopia.website holds international synthesis, comparison and tools. Where a synthesis here rests on a Polish dossier, it cites it as a source.

VISIT THE POLISH PLATFORM ↗
{{ d.tag }}
{{ d.body }}